AACR 101st Annual Meeting 2010: Major Symposia

Identifying Proteomic Markers of Prognosis and Therapeutic Outcome

Co-Chairpersons: Daniel C. Liebler, Vanderbilt University, Nashville, TN, and John D. Haley, OSI Pharmaceuticals, Inc., Farmingdale, NY

• Nanoscale proteomic analysis of biologic response to targeted therapeutics
  Alice C. Fan, Stanford Cancer Center, Stanford, CA
• Adaptive protein and phosphoprotein networks which promote therapeutic sensitivity or acquired resistance
  John D. Haley
• High-end proteomics enables identification of breast cancer therapy resistance predictive proteins
  Arzu Umar, Erasmus Medical Center, Rotterdam, The Netherlands
• Biological insight from quantitative analysis of glioblastoma signaling networks
  Forest M. White, Massachusetts Institute of Technology, Cambridge, MA

Invasion and Metastasis

Chairperson: Sara A. Courtneidge, Sanford-Burnham Medical Research Institute, La Jolla, CA

• Imaging the metastatic process
  Erik Sahai, Cancer Research UK London Research Institute, London, United Kingdom
• Novel mechanisms regulating breast cancer progression, metastasis, and response to therapy
  Zena Werb, University of California, San Francisco, CA
• Studying tumor evolution in mouse models of cancer
  Tyler Jacks, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA
• Regulation of invadopodia formation and cancer cell invasion
  Sara A. Courtneidge

Manipulating Tumor Immunity

Chairperson: Carl H. June, University of Pennsylvania, Philadelphia, PA

• The desirable death of the cancer cell: Immunogenic cell death for optimal chemotherapy
  Laurence Zitvogel, Institut Gustave-Roussy, Villejuif, France
• Wnt signaling generates “stem-like” self-renewing T cells that can eradicate tumors
  Nicholas P. Restifo, National Cancer Institute, Bethesda, MD
• Modulating innate and adaptive immunity through the manipulation of dendritic cells
  Nina Bhardwaj, New York University School of Medicine, New York, NY
• Engineered T cell therapy cancer
  Carl H. June

Noncoding RNAs

Chairperson: Carlo M. Croce, The Ohio State University Comprehensive Cancer Center, Columbus, OH

• Causes and consequences of microRNA dysregulation in cancer
  Carlo M. Croce
• Noncoding RNA principles in medical practice: From diagnosis to therapy
  George A. Calin, UT M. D. Anderson Cancer Center, Houston, TX
• microRNAs as potential therapeutics and targets in cancer
  Frank Slack, Yale University, New Haven, CT
• Title to be announced
  Danilo Perrotti, The Ohio State University Medical Center, Columbus, OH

Molecular Approaches for Cancer Prevention: Markers, Models, and Mechanisms

Chairperson: Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY

• Introduction: Molecular approaches for prevention research
  Cory Abate-Shen
• Mechanisms behind the anticancer effects of caloric restriction
  David M. Sabatini, The Whitehead Institute for Biomedical Research, Cambridge, MA
• Does targeting the cancer epigenome represent promise for prevention?
  Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD
• From mouse to human: The search for early detection markers
  Samir M. Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA
• Novel targets in metastasis prevention
  Jonathan M. Kurie, UT M. D. Anderson Cancer Center, Houston, TX

Differentiation in Cancer and Cell Fate Reprogramming

Chairperson: Carlo C. Maley, The Wistar Institute, Philadelphia, PA

• The role of differentiation in neoplasms and somatic evolution
  Carlo C. Maley
• The leukemia stem cell genome
  Norma F. Neff, Stanford University, Stanford, CA
• Reprogramming iPS and cancer stem cells
  Inder Verma, Salk Institute Cancer Center, La Jolla, CA
• Factors influencing nuclear reprogramming
  Konrad Hochedlinger, Massachusetts General Hospital, Boston, MA

Environment and Emerging Exposures

Chairperson: Johanna Wyss Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA

• Cancer rates in transition countries: New exposures and new epidemics
  Paolo Boffetta, Mount Sinai School of Medicine, New York, NY
• Diet and nondietary factors and breast cancer in Asian Americans
  Anna H. Wu, USC/Norris Comprehensive Cancer Center, Los Angeles, CA
• Circadian disruption and breast carcinogenesis
  Eva S. Schernhammer, Harvard Medical School, Boston, MA
• Diet and xenobiotic-metabolizing enzymes: Learning from controlled feeding studies in humans
  Johanna W. Lampe

Infection, Inflammation, and Immunity: Crossroads to Cancer

Co-Chairpersons: Cornelia M. Ulrich, Fred Hutchinson Cancer Research Center, Seattle, WA, and Eric A. Engels, National Cancer Institute, Rockville, MD

• Cancer in immunosuppressed populations: Epidemiologic clues to causation
  Eric A. Engels
• Xenotropic murine virus-related virus in prostate cancer and chronic fatigue syndrome
  Francis W. Ruscetti, NCI-Frederick, Frederick, MD
• Genetics of inflammation: Candidates, genome-wide association studies, and personalized prevention?
  Cornelia M. Ulrich
• Is intraprostatic inflammation a risk factor for prostate cancer?
  Elizabeth A. Platz, Johns Hopkins University School of Public Health, Baltimore, MD

Aging and Cancer

Chairperson: Judith Campisi, Buck Institute for Age Research, Novato, CA

• Genomic instability, aging, and cancer
  Jan Vijg, Albert Einstein College of Medicine, New York, NY
• Can sitruin activation treat cancer?
  Leonard P. Guarente, Massachusetts Institute of Technology, Cambridge, MA
• Tumor suppressors at the interface of aging and cancer
  Manuel Serrano, Spanish National Cancer Center, Madrid, Spain
• DNA damage response links inflammation, cancer, and aging
  Judith Campisi

Chemical Biology Approaches in Cancer

Chairperson: Gregory L. Verdine, Harvard University, Cambridge, MA

• Drugging “undruggable” transcription
  Gregory L. Verdine
• Bifunctional agents for targeting endogenous antibodies to tumor cells
  Laura L. Kiessling, University of Wisconsin, Madison, WI
• Turning enzymes on with small molecules
  James A. Wells, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Nanotechnology and Cancer

Co-Chairpersons: Chad A. Mirkin, Northwestern University, Evanston, IL, and Piotr Grodzinski, National Cancer Institute, Bethesda, MD

• NCI Alliance for Nanotechnology in Cancer: The opportunity
  Anna D. Barker, National Cancer Institute, Bethesda, MD
• The polyvalent nanoparticle conjugate: A new frontier in cancer diagnostics and therapeutics
  Chad A. Mirkin
• Nanomolecular imaging
  Sanjiv Sam Gambhir, Stanford University, Stanford, CA
• Path to the clinic for nanoparticles containing nucleic acids
  Mark E. Davis, California Institute of Technology, Pasadena, CA

The Bayard D. Clarkson Symposium on Stem Cells and Cancer
The Role of Tissue Stem Cells in Cancer Initiation

Chairperson: Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands

• Lung tumor propagating cells: Genotype matters
  Carla F. Kim, Children’s Hospital Boston, Boston, MA
• Cancer stem cells in breast cancer metastasis
  Joerg Huelsken, Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland
• Stem cells and the origin of prostate cancer
  Michael Shen, Columbia University, New York, NY
• Wnt, Lgr5 stem cells, and cancer
  Hans Clevers

Tumor Immune Suppression and Escape

Chairperson: Mark J. Smyth, Peter MacCallum Cancer Center, East Melbourne, Australia

• Pathways that suppress tumor immunity
  Mark J. Smyth
• Transcriptional control of tumor-induced myeloid-derived suppressor cells
  Vincenzo Bronte, Istituto Oncologico Veneto, Padova, Italy
• Endothelial regulation of antitumor immune response
  George Coukos, University of Pennsylvania, Philadelphia, PA
• B7-H1/PD-1 blockade in cancer therapy
  Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Anaplastic Lymphoma Kinase

Chairperson: Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA

• Chemical inhibitors of ALK
  Nathanael S. Gray, Dana-Farber Cancer Institute, Boston, MA
• ALK in neuroblastoma
  Yael P. Mosse, Children’s Hospital of Philadelphia, Philadelphia, PA
• Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  Stephan W. Morris, St. Jude Children’s Research Hospital, Memphis, TN
• Discovery and clinical application of EML4-ALK oncogene in lung cancer
  Hiroyuki Mano, University of Tokyo, Jichi Medical University, Tokyo, Japan

Systems, Pathways, and Network Approaches to Understanding Signaling, Tumorigenesis, and Response to Therapy

Chairperson: Jill P. Mesirov, Broad Institute of MIT and Harvard, Cambridge, MA

• Using comparative oncogenomics to guide personalized cancer medicine
  Ronald A. DePinho, Dana-Farber Cancer Institute, Boston, MA
• Constructing and deconstructing cancer using mouse models and RNAi
  Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
• Systems biology of DNA damage and repair
  Michael P. Yaffe, Massachusetts Institute of Technology, Cambridge, MA
• Systematic reconstruction of regulatory networks in mammalian cells: Lessons from the pathogen response
  Aviv Regev, Massachusetts Institute of Technology, Cambridge, MA

Metabolism and Cancer

Chairperson: Craig B. Thompson, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

• LKB1/AMPK pathway coordinates cell growth and metabolism
  Reuben J. Shaw, Salk Institute for Biological Studies, La Jolla, CA
• Cancer-associated mutations in IDH1 and IDH2 produce 2HG
  Valeria R. Fantin, Agios Pharmaceuticals, Cambridge, MA
• Therapeutic targeting of glutamine metabolism induced by Myc
  Chi Van Dang, Johns Hopkins University School of Medicine, Baltimore, MD
• Metabolites as oncogenes
  Craig B. Thompson

The Ruth Sager Memorial Symposium on Cancer Genetics and Epigenetics
The Epigenetic Terrain of Cancer: Origins and Biological and Translational Implications

Co-Chairpersons: Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD, and Peter A. Jones, USC/Norris Comprehensive Cancer Center, Los Angeles, CA

• Title to be announced
  Thea D. Tlsty, University of California School of Medicine, San Francisco, CA
• Mechanisms of epigenetic gene silencing in human cancers
  Beverly M. Emerson, Salk Institute Cancer Center, La Jolla, CA
• Reexpressing abnormally silenced genes: Implications for cancer biology and management
  Stephen B. Baylin
• Activating silenced genes in cancer
  Peter A. Jones

Unconventional Therapeutic Targets

Chairperson: Lyubomir T. Vassilev, Hoffmann-La Roche, Inc., Nutley, NJ

• Targeting the p53-MDM2 interaction for cancer therapy
  Lyubomir T. Vassilev
• Targeting transcriptional regulators for simultaneous modulation of p53 and NF-κB in cancer treatment
  Andrei V. Gudkov, Roswell Park Cancer Institute, Buffalo, NY
• Targeting the Id transcription factors using large and small molecule inhibitors
  Robert Benezra, Memorial Sloan-Kettering Cancer Center, New York, NY
• Inhibition of NEDD8-activating enzyme for cancer treatment: Preclinical validation to clinical application of MLN4924
  Peter G. Smith, Millennium Pharmaceuticals, Inc., Cambridge, MA

Applications of Systems Biology Approaches to Cancer

Chairperson: Andrea Califano, Columbia University, New York, NY

• Cell to cell variability in the responses of tumor cells to death ligands
  Peter K. Sorger, Harvard Medical School, Boston, MA
• Breast cancer systems biology
  Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA
• Single-cell signaling and pathology in primary cell cancers for mechanism and diagnostics
  Garry P. Nolan, Stanford School of Medicine, Stanford, CA
• A systems biology approach reveals master regulators of the mesenchymal phenotype of glioblastoma
  Andrea Califano

Imaging

Chairperson: Sanjiv Sam Gambhir, Stanford University, Stanford, CA

• Molecular imaging of cell surface phenotypes using ImmunoPET
  Anna M. Wu, David Geffen School of Medicine at UCLA, Los Angeles, CA
• Translational molecular imaging for oncology
  Martin G. Pomper, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
• Novel radiotracers for clinical molecular imaging in oncology
  Steven M. Larson, Memorial Sloan-Kettering Cancer Center, New York, NY

Innovative Clinical Trials with Molecular Targeted Agents

Chairperson: Donald A. Berry, UT M. D. Anderson Cancer Center, Houston, TX

• Opportunities and challenges for biomarker-driven presurgical studies
  Mitchell Dowsett, Royal Marsden NHS Trust, London, United Kingdom
• The randomized discontinuation design
  Mark J. Ratain, University of Chicago, Chicago, IL
• Breaking down barriers and enabling innovation: Lessons from the I-SPY TRIAL
  Laura Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
• Title to be announced
  Donald A. Berry

Minorities in Cancer Research Scientific Symposium
The Path Towards Personalized Oncology: Connecting the Dots

Chairperson: John D. Carpten, Translational Genomics Research Institute, Phoenix, AZ

• Title to be announced
  Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA
• Title to be announced
  Ben Ho Park, Johns Hopkins University, Baltimore, MD
• Title to be announced
  Alex A. Adjei, Roswell Park Cancer Center, Buffalo, NY

New Molecular Targets

Chairperson: Patricia M. LoRusso, Barbara Ann Karmanos Cancer Institute, Detroit, MI

• Regulation of ubiquitination and cancer
  Vishva M. Dixit, Genentech, Inc., South San Francisco, CA
• Targeting the Wnt pathway
  Michael Kahn, University of Southern California, Los Angeles, CA
• Oncogenic signal transduction via the hepatocyte growth factor/Met receptor kinase pathway
  Donald P. Bottaro, National Cancer Institute, Bethesda, MD
• Selective BRaf targeting: Does it make a difference?
  Keith B. Nolop, Plexxikon, Inc., Berkeley, CA

The Ras Pathway in Cancer

Chairperson: Dafna Bar-Sagi, New York University School of Medicine, New York, NY

• In search for inhibitors of K-Ras for colon and pancreatic cancer treatment
  Channing J. Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
• Targeting oncogenic Ras in Cancer
  Kevin M. Shannon, University of California, San Francisco, CA
• The signaling landscape of oncogenic Ras
  Dafna Bar-Sagi
• Pathways promoting pancreatic cancer
  David A. Tuveson, Cancer Research UK, Cambridge, United Kingdom

Combinatorial Approaches

Chairperson: Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA

• Identifying rational combination therapies with mTOR inhibitors
  Karen Cichowski, Brigham and Women’s Hospital, Boston, MA
• Title to be announced
  Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY
• Title to be announced
  Jeffrey A. Engelman
• Targeting the RAS signal transduction network in cancer cells
  W. Michael Korn, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Energy Balance and Cancer Prevention: A Transdisciplinary Approach

Chairperson: Stephen D. Hursting, UT Austin Cancer Center, Austin, TX

• Transdisciplinary studies of weight loss and exercise interventions in women at increased risk for breast cancer
  Anne McTiernan, Fred Hutchinson Cancer Research Center, Seattle, WA
• Impact of dietary carbohydrate availability on breast cancer: Does energy flux matter?
  Henry J. Thompson, Colorado State University, Fort Collins, CO
• Regulation of estrogen production by adipose stromal cells: Potential impact on breast cancer risk
  Rong Li, University of Texas Health Science Center, San Antonio, TX
• Biomarkers of energy balance and breast cancer survival
  Melinda L. Irwin, Yale University School of Public Health, New Haven, CT

Mechanisms of Tumor Angiogenesis and Therapeutic Resistance

Chairperson: Douglas Hanahan, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

• Differential efficacy of the angiogenesis inhibitor thrombospondin-1 in different organs
  Sandra W. Ryeom, University of Pennsylvania School of Medicine, Philadelphia, PA
• Heterogeneity of tumor-associated macrophages in tumors: Implications for antiangiogenic therapy
  Michele De Palma, San Raffaele Scientific Institute, Milan, Italy
• Angiogenesis inhibitors do more than inhibit angiogenesis: The list gets longer
  Donald M. McDonald, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
• Intrinsic and evasive resistance to antiangiogenic therapy
  Douglas Hanahan

Understanding the Cancer Genome with Next-Generation DNA Sequencing

Chairperson: Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

• Title to be announced
  Elaine Mardis, Washington University School of Medicine, St. Louis, MO
• Title to be announced
  David Huntsman, BC Cancer Agency, Vancouver, BC, Canada

The p53 Pathway: From Start to Finish

Chairperson: Charles J. Sherr, St. Jude Children’s Research Hospital, Memphis, TN

• Functions of wild-type and mutant p53
  Karen H. Vousden, The Beatson Institute for Cancer Research, Glasgow, United Kingdom
• The Mdm2/Mdm4 complex: A rheostat for p53 activitiy
  Guillermina Lozano, UT M. D. Anderson Cancer Center, Houston, TX
• Regulation of cellular self-renewal by the RF
  Charles J. Sherr
• How p53 suppresses tumors
  Gerard I. Evan, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Radiation Biology

Chairperson: Daphne A. Haas-Kogan, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

• Targeting DNA repair pathways in cancer therapy
  Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA
• Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
  Simon N. Powell, Memorial Sloan-Kettering Cancer Center, New York, NY
• Targeting the tumor stroma to inhibit metastatic tumor growth
  Amato J. Giaccia, Stanford University School of Medicine, Stanford, CA
• Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  Daphne A. Haas-Kogan

The Stanley J. Korsmeyer Memorial Symposium
Apoptosis and Autophagy: Cell Death and Survival Signaling in Cancer

Chairperson: Eileen P. White, UMDNJ-The Cancer Institute of New Jersey, New Brunswick, NJ

• The role of autophagy in cancer progression and therapy
  Eileen P. White
• Autophagy, cancer cell survival, and mitochondrial homeostasis
  Jayanta Debnath, University of California, San Francisco, CA
• Protein N-a-acetylation couples metabolism and apoptosis
  Junying Yuan, Harvard Medical School, Boston, MA
• Metabolic regulation of tumor cells survival
  Tak W. Mak, University of Toronto, Toronto, ON, Canada

Forty Years of Somatic Cell Genetics and Tumor Suppressor Genes: From Cells to Genes to Whole Genome Sequencing
A Tribute to Dr. Eric Stanbridge

Co-Chairpersons: Channing Der, University of North Carolina, Chapel Hill, NC, and Bernard Weissman, University of North Carolina, Chapel Hill, NC

• The ancient roots of tumor suppressor genes
  Robert Weinberg, Massachusetts Institute of Technology, Cambridge, MA
• The surprising future of tumor suppressor genes
  Norman Sharpless, University of North Carolina, Chapel Hill, NC
• Leveraging large scale DNA sequencing as a tool in human cancer genetics
  Andrew Furtreal, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
• Chromatin remodeling: At the crossroads of genetic and epigenetic tumor suppression
  Bernard Weissman

Genome-wide Association Studies and Beyond

Co-Chairpersons: Montserrat Garcia-Closas, National Cancer Institute, Rockville, MD, and Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN

• Introduction: How tumor characterization can help
  Montserrat Garcia-Closas
• Genetic architecture of cancer and other complex diseases: Lessons learned and future directions
  Teri Manolio, National Human Genome Research Institute, Bethesda, MD
• Discerning the functional consequences of risk alleles in non–protein-coding regions
  Matthew L. Freedman, Massachusetts General Hospital, Boston, MA
• Comprehensive cataloging of regions identified in genome-wide association studies
  Meredith Yeager, National Cancer Institute, Bethesda, MD
• Using genome-wide association studies to study cancer survival
  Gloria M. Petersen

Role of Telomeres and Telomerase in Chromosomal Stability and Disease

Chairperson: Maria Blasco, Spanish National Cancer Center, Madrid, Spain

• Insights from responses of cancer cells to perturbations of telomerase
  Elizabeth H. Blackburn, University of California, San Francisco, CA
• Telomerase and the consequences of telomere dysfunction
  Carol W. Greider, Johns Hopkins University School of Medicine, Baltimore, MD
• Role of telomerase in normal and neoplastic stem cells
  Jerry W. Shay, UT Southwestern Medical Center, Dallas, TX
• Role of shelterin in cancer and aging: Generation of conditional knockout mice for TRF1, TPP1, and RAP1
  Maria Blasco

The Chemistry and Biology of Hypoxia: Biological Mechanisms, Imaging, and Drug Development

Chairperson: Kent S. Gates, University of Missouri, Columbia, MO

• Do we need to know what pO2 “hypoxia” is?
  Cameron J. Koch, University of Pennsylvania, Philadelphia, PA
• Hypoxia-metabolic targets for drug development: Identification of targets and their validation
  Ian J. Stratford, University of Manchester School of Pharmacy, Manchester, United Kingdom
• New prodrugs for targeting tumor hypoxia
  William Robert Wilson, University of Auckland Cancer Society Research Center, Auckland, New Zealand
• The impact of O2 availability on human cancer
  M. Celeste Simon, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

Translational Control of Cancer via the mTOR/eIF4E Pathway and Ribosome Biogenesis

Chairperson: Nahum Sonenberg, McGill University, Montréal, QC, Canada

• Mechanisms of translational control through phosphorylation of 4E-BPs and eIF4E
  Nahum Sonenberg
• Title to be announced
  George Thomas, University of Cincinnati, Cincinnati, OH
• Genetic dissection of the oncogenic PI3K-Akt-mTOR pathway reveals druggable addiction to translational control via 4E-BP1-eIF4E
  Davide Ruggero, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
• eIF4E in breast cancer is a master regulator of tumor cell invasion through increased translation of β1 integrin mRNA and TGFβ activation
  Robert J. Schneider, New York University School of Medicine, New York, NY